News on May 14thCrashteamracing2There are seven advantages that may affect tomorrow's stock market, specifically:

1. Shanghai Pharmaceutical: Shakubaqu Valsartan Sodium tablets, a holding subsidiary, are approved for production.

Shanghai Pharmaceutical (601607) announced on the evening of May 14 that recently, Shakubaqu Valsartan Sodium tablets of Changzhou Pharmaceutical Factory Co., Ltd., a subsidiary of the company, received a "Drug Registration Certificate" issued by the State Drug Administration, and the drug was approved for production. Sakubatrol valsartan sodium tablets are mainly used to treat symptoms such as chronic heart failure and essential hypertension.

2. Chinese medicine Hyundai: the subsidiary paramivir injection obtains the drug registration certificate.

Sinopharm Hyundai (600420) announced on the evening of May 14 that recently, the wholly-owned subsidiary of Sinopharmaceutical Group Rongsheng Pharmaceutical Co., Ltd. (referred to as Guoyao Rongsheng) received the "Drug Registration Certificate" of Paramivir injection approved and issued by the State Drug Administration. The national drug Rongsheng has obtained the drug registration certificate of paramivir injection and regarded as through consistency evaluation, expanding the company's influenza drug product group in the field of anti-infection, which is helpful to enhance the company's comprehensive market competitiveness in the field of anti-infection.

3. Weihai Guangtai: a wholly owned subsidiary won the bid 3Crashteamracing2.75 billion yuan fire engine project

Weihai Guangtai (002111) announced on the evening of May 14 that Beijing Zhongzhuo Times Fire equipment Technology Co., Ltd., a wholly-owned subsidiary, recently won a bid for a fire engine project with a bid amount of 375 million yuan, accounting for 15.6% of the company's business income in 2023. it is the company's largest special market order since June 2021.

4. Yihualu passed the CMMI V3.0 level 5 certification of the highest level in the world.

According to Yihualu news, recently, after the evaluation of international authoritative organizations, Yihualu has passed the CMMI-DEV3.0 version 5 certification in the global software field, and has become one of the first domestic enterprises to pass DEV3.0 version certification. This is the third review of Yihualu after obtaining CMMI-DEV level 5 certification for the first time in 2018 and CMMI-DEV version 2.0 level 5 certification in 2021, indicating that Yihualu is in line with the latest international standards in software technology research and development and project management capabilities, reaches the international leading level, and is able to provide customers with higher quality and more mature products and services.

5. Jilin Chemical Fiber: the actual controller will be changed from Jilin SASAC to Jilin SASAC.

Jilin Chemical Fiber (000420) announced on the evening of May 14 that the real controller of the company, Jilin City SASAC, signed a memorandum of equity transfer with Jilin State-owned Capital Operation Group Co., Ltd. (referred to as "Capital Operation Group"). Jilin City SASAC intends to transfer the control of Jilin Chemical Fiber Group Co., Ltd. (referred to as "Chemical Fiber Group") and Jilin Guoxingxin Materials Industry Investment Co., Ltd. After the completion of the transaction, the controlling shareholder of the company will still be the Chemical Fiber Group, and the Capital Operation Group will become the indirect controlling shareholder of the company. The actual controller of the company will be changed from Jilin SASAC to Jilin SASAC.

6. Rongtai, Zhejiang: the project of mica materials and composite materials for new energy vehicles will be built in Thailand.

Zhejiang Rongtai (603119) announced on the evening of May 14th that in order to meet the needs of the company's overseas business development, the company intends to set up a subsidiary in Thailand through a wholly-owned subsidiary of Singapore Rongtai, the final investment in the construction of 18000 tons of new energy vehicle mica materials and new composite materials project, the project is expected to accumulate a total investment of about 300 million yuan (equivalent to US $42.2357 million).

7. Tonghua Dongbao: de Gu Insulin Lilaru Peptide injection Phase I Clinical trial completed the first patient administration

Tonghua Dongbao (600867) announced on the evening of May 14th that the company has launched a phase I clinical trial in China after receiving a notice of approval for the clinical trial of Delarutide injection issued by the State Drug Administration. Recently, the first patient administration was successfully completed.